Suppr超能文献

消费者疾病风险检测:ACOG 委员会意见摘要,第 816 号。

Consumer Testing for Disease Risk: ACOG Committee Opinion Summary, Number 816.

出版信息

Obstet Gynecol. 2021 Jan 1;137(1):203-204. doi: 10.1097/AOG.0000000000004201.

Abstract

With the increased emphasis on patient-driven health care and readily available access to patients as consumers through the internet and media, many genetic testing companies are marketing directly to consumers. Direct-to-consumer genetic testing may result in unique concerns and considerations, because of limited knowledge about available genetic tests among patients and health care professionals, challenges in interpretation of genetic test results, and lack of oversight of some companies, as well as issues of privacy and confidentiality. It is important to note that tests from different companies that evaluate the same condition or genes can vary greatly in scope and technical quality. When undergoing direct-to-consumer genetic testing, the consumer should be apprised of risk from screening or susceptibility test results that can neither prove nor eliminate disease potential but may be distressing for consumers. Because of these considerations and the fact that the interpretation of test results often requires specific training and medical knowledge, direct-to-consumer genetic testing ideally should be performed after counseling to review the test's potential benefits, risks, and limitations. Confirmatory genetic testing should be performed under the supervision of an appropriate obstetrician-gynecologist or other health care professional who is skilled in interpretation of genetic testing and risk assessment for the diseases of interest. This Committee Opinion has been updated to include information on counseling for patients who present with direct-to-consumer genetic test results, clinical vignettes, and an overview of currently available testing options as well as those potentially available in the near future.

摘要

随着患者驱动型医疗保健的日益重视,以及通过互联网和媒体使患者作为消费者能够轻松获得医疗服务,许多基因检测公司开始直接面向消费者进行营销。直接面向消费者的基因检测可能会带来独特的关注和考虑,因为患者和医疗保健专业人员对可用的基因检测了解有限,基因检测结果的解释存在挑战,以及一些公司缺乏监管,还有隐私和保密问题。值得注意的是,评估同一病症或基因的不同公司的检测在范围和技术质量上可能有很大差异。当进行直接面向消费者的基因检测时,应告知消费者筛查或易感性检测结果的风险,这些结果既不能证明也不能消除疾病的潜在可能性,但可能会令消费者感到不安。由于这些考虑因素,以及测试结果的解释通常需要特定的培训和医学知识,因此,在进行直接面向消费者的基因检测之前,最好进行咨询,以评估测试的潜在益处、风险和局限性。确认性基因检测应由熟练解读基因检测和相关疾病风险评估的适当妇产科医生或其他医疗保健专业人员进行监督。本委员会意见已更新,包括为呈现直接面向消费者的基因检测结果的患者提供咨询、临床案例以及当前可用检测选项概述以及近期可能提供的检测选项的信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验